Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) antibody-related diseases are very rare in autoimmune neurological diseases. We collected and analyzed the data of 3 patients with peculiar clinical manifestation positive for AMPA2-R antibody in the Department of Neurology, Xuanwu Hospital, Capital Medical University. In our reported case series, 2 patients were male and 1 was female. The initial clinical features of 3 patients were all consistent with an encephalopathy predominantly involving the limbic system. Interestingly, as the disease continues to advance, case 1 presented with limb paralysis, case 2 developed typical cerebellar ataxia, and case 3 had symptoms of autonomic instability. These 3 types of clinical features were very rare in patients with AMPAR-Ab. After immunotherapy, cases 1 and 3 responded well and case 2 was not responsive. During the follow-up, residual memory loss of cases 1 and 3 improved gradually, and they returned to work. To eliminate the influence of the presence of other pathogenic antibodies, we analyzed the available individual clinical information of 37 patients with the single AMPAR-Ab by systematic literature review. A majority of patients had sudden short-term memory loss as the initial symptom and developed limbic encephalitis. Residual memory deficit was the most common symptom after discharge. The combination of at least 2 types of immunotherapy was recommended as the first-line treatment, and patients would benefit from the tumor screening. In addition, compared with the patients positive for single AMPAR-Ab, the patients with both AMPAR-Ab and other antibodies had a higher risk of malignant tumor and might have a poor therapeutic response, which led to a poor prognosis.

1.
Palmer
CL
,
Cotton
L
,
Henley
JM
.
The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
.
Pharmacol Rev
.
2005
;
57
(
2
):
253
77
. .
2.
Sprengel
R
.
Role of AMPA receptors in synaptic plasticity
.
Cell Tissue Res
.
2006
;
326
(
2
):
447
55
. .
3.
Lai
M
,
Hughes
EG
,
Peng
X
,
Zhou
L
,
Gleichman
AJ
,
Shu
H
, et al
AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location
.
Ann Neurol
.
2009
;
65
(
4
):
424
34
. .
4.
Höftberger
R
,
van Sonderen
A
,
Leypoldt
F
,
Houghton
D
,
Geschwind
M
,
Gelfand
J
, et al
Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients
.
Neurology
.
2015
;
84
(
24
):
2403
12
. .
5.
Graus
F
,
Boronat
A
,
Xifró
X
,
Boix
M
,
Svigelj
V
,
García
A
, et al
The expanding clinical profile of anti-AMPA receptor encephalitis
.
Neurology
.
2010
;
74
(
10
):
857
9
. .
6.
Gresa-Arribas
N
,
Titulaer
MJ
,
Torrents
A
,
Aguilar
E
,
McCracken
L
,
Leypoldt
F
, et al
Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study
.
Lancet Neurol
.
2014
;
13
(
2
):
167
77
. .
7.
Gu
Y
,
Zhong
M
,
He
L
,
Li
W
,
Huang
Y
,
Liu
J
, et al
Epidemiology of antibody-positive autoimmune encephalitis in southwest China: a multicenter study
.
Front Immunol
.
2019
;
10
:
2611
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.